Clinical trials: Central Obesity
Obesity
Pilot Study to Evaluate A Novel Gastric Space Occupying Device
This will be an observational, prospective, non-randomized, pilot study to gain initial device experience on a novel space-occupying device in persons who are overweight or obese. No formal hypothesis testing will be conducted.
- Trial name
- NCT01444274
- Testing
- Obalon Gastric Balloon(s)
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Obalon Therapeutics, Inc.
Abdominal Obesity
Eon™ FR 1064 Full Abdomen Clinical Study Protocol
This is a marketing study intended to provide additional data for marketing purposes for the eon™ FR is FDA 510(k) which has been cleared for non-invasive lipolysis of the abdomen to achieve disruption of adipocyte cells intended…
- Trial name
- NCT04842110
- Testing
- Experimental: eonTM FR 1064 nm device
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dominion Aesthetic Technologies, Inc.
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos
Hypothalamic Injury-induced Obesity (HIO)
48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
Double-blind, randomized, placebo-controlled, single- center study followed by an open-label extension period. The study will have two parts: Part 1: 24 weeks double-blind treatment (DB), followed by Part 2: 24 weeks open-label…
- Trial name
- NCT03845075
- Testing
- Tesofensine/Metoprolol
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Saniona
Carotid Artery Plaque, Arteriosclerosis
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
Objectives: Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) Secondary: To…
- Conditions
- Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
- Trial name
- AUDITOR (NCT00228176)
- Testing
- Rimonabant
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Sanofi
Obesity, Metabolic Syndrome
Effects of Telemonitoring Service for Obesity Care
A randomized, open, parallel, multi-center trial to evaluate weight loss efficacy of Smart Care Service in obese patients with metabolic syndrome.
- Trial name
- Smart-OB (NCT01344811)
- Testing
- Telemonitoring, control group
- Where
- 2 sites in South Korea
- Volunteers
- 661 people
- Sponsor
- Chang Hee, Lee
Obesity
Safety and Performance of the OTTAVA Robotic System
This study assesses safety and performance of the OTTAVA Robotic System, through 30 days postoperative, in subjects undergoing robotic-assisted Roux-en-Y Gastric Bypass (RYGB) procedure.
- Trial name
- FORTE (NCT06709261)
- Testing
- OTTAVA Robotic System
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Auris Health, Inc.
Obesity
A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)
This is a 1-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients after a very low calorie diet.
- Trial name
- NCT00092872
- Testing
- MK0557
- Volunteers
- 359 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity or Overweight
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult…
- Trial name
- NCT07081958
- Testing
- RO7795081
- Where
- 36 sites in United States
- Volunteers
- 352 people
- Sponsor
- Hoffmann-La Roche
Obesity, Eating Disorders
Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients
The primary objective is to assess the effect of rimonabant compared to placebo on weight loss over a period of 6 months when prescribed with a mild hypocaloric diet in obese patients with binge eating disorder.
- Trial name
- NCT00481975
- Testing
- rimonabant (SR141716)
- Where
- 7 sites in United States, Finland and 5 more
- Volunteers
- 289 people
- Sponsor
- Sanofi
GERD, Gastroesophageal Reflux Disease
RELIEF Europe Study
The purpose of this study is to evaluate the LINX device in patients who have previously undergone laparoscopic sleeve gastrectomy (LSG) for obesity and have chronic gastroesophageal reflux disease (GERD).
- Conditions
- GERD, Gastroesophageal Reflux Disease, Obesity, LSG
- Trial name
- NCT02762487
- Testing
- The LINX® Reflux Management System
- Where
- 4 sites in Germany, Italy
- Volunteers
- 7 people
- Sponsor
- Torax Medical Incorporated
Obesity
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet
1. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week low calorie diet (LCD) of 950 kcal/day with or without S-2367 followed by 54 weeks while on a 800…
- Trial name
- NCT00748605
- Testing
- S-2367 1600 mg q.d. 54 Weeks, S-2367 1600 mg q.d. 60 weeks, LCD (low calorie diet)
- Where
- 40 sites in United States
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- Shionogi
Diabetes, Obesity
Prospective Metabolic Surgery in T2DM Chinese Subjects
The primary goal of this study is to assess impact of metabolic surgery on glycemic control in diabetic patients.
- Trial name
- NCT02217943
- Testing
- Roux-en-Y gastric bypass, Sleeve gastrectomy
- Where
- 6 sites in China
- Volunteers
- 101 people
- Sponsor
- Ethicon Endo-Surgery
Overweight/Obesity
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
The study is being conducted to evaluate the bioequivalence between a single-dose pen and a multi-dose pen of HRS9531 injection solution.
- Trial name
- NCT06792955
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Prader-Willi Syndrome
Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome
Evaluate the efficacy and safety after treatment of Eutropin® inj. compared to Genotropin® in infants/toddlers with Prader-Willi syndrome
- Trial name
- NCT02204163
- Testing
- Eutropin, Genotropin
- Where
- 3 sites in South Korea
- Volunteers
- 34 people
- Sponsor
- LG Life Sciences
Otherwise Healthy Overweight or Obese
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose (MAD) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of PHP-303 in otherwise healthy overweight or obese…
- Trial name
- NCT03775278
- Testing
- PHP-303
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- pH Pharma
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.
This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.
- Trial name
- NCT02717858
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Novo Nordisk A/S
Obesity
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with…
- Trial name
- PRADO (NCT00405808)
- Testing
- Rimonabant
- Where
- 27 sites in Austria, Belgium and 25 more
- Volunteers
- 2,666 people
- Sponsor
- Sanofi
Overweight , Obesity, Adults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
- Trial name
- PRESERVE (NCT07837973)
- Testing
- ALV-100
- Where
- 20 sites in United States
- Volunteers
- 220 people
- Sponsor
- Alveus Therapeutics, Inc.
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.